Browsing Tag
Jacobio Pharma
3 posts
AstraZeneca Q1 2026 results: Can oncology and rare disease growth keep AZN’s 2030 ambition on track?
AstraZeneca’s growth engine is firing, but pricing pressure and launch risk still loom. Can oncology and rare disease carry AZN to 2030?
Jacobio Pharma secures $2bn global licensing agreement with AstraZeneca for JAB-23E73
Jacobio Pharma’s $2B global licensing deal with AstraZeneca could reshape KRAS inhibitor strategy in oncology. Read the full breakdown of the partnership now.
Jacobio Pharma doses first patient with Aurora A inhibitor JAB-2485 in phase 1/2a trial
Jacobio Pharma said that it has completed the first patient dosage of Aurora A inhibitor JAB-2485, its in-house…